drugset / Trial / NCT05263609
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research is to test the response of study participants' tumor to pembrolizumab alone, and in combination with axitinib, and to see what effects (good and bad) these drugs have on patients with advanced kidney cancer.
Timeline
- Start
- 2022-06
- Primary completion
- 2026-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |